Baker Bros. Advisors LP T Scan Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $9.86 Billion
- Q2 2025
A detailed history of Baker Bros. Advisors LP transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 2,784,792 shares of TCRX stock, worth $6.52 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,784,792
Previous 2,784,792
-0.0%
Holding current value
$6.52 Million
Previous $3.84 Million
5.05%
% of portfolio
0.04%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding TCRX
# of Institutions
80Shares Held
37.7MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$18.4 Million3.37% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$12.2 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$10.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$5.03 Million0.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA2.09MShares$4.88 Million3.67% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $44.3M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...